Page last updated: 2024-11-04

vorinostat and Angiogenesis, Pathologic

vorinostat has been researched along with Angiogenesis, Pathologic in 16 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"Treatment of vorinostat upregulates PLD1 through PKCζ-Sp1 axis."5.62Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma. ( Hwang, WC; Jang, Y; Kang, DW; Kang, Y; Kim, JA; Min, DS; Noh, YN, 2021)
"The recommended phase II dosage was oral pazopanib at 600 mg daily plus oral vorinostat at 300 mg daily."2.80Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. ( Araujo, D; Fu, S; Hess, K; Hong, D; Hou, MM; Hwu, P; Janku, F; Karp, D; Kee, B; Kurzrock, R; Meric-Bernstam, F; Naing, A; Piha-Paul, S; Subbiah, V; Tsimberidou, A; Wheler, J; Wolff, R; Zinner, R, 2015)
"Treatment of vorinostat upregulates PLD1 through PKCζ-Sp1 axis."1.62Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma. ( Hwang, WC; Jang, Y; Kang, DW; Kang, Y; Kim, JA; Min, DS; Noh, YN, 2021)
" Consistent additive to synergistic interactions were observed in HCT116 cells when PENT was combined with SAHA at all drug tested concentrations."1.46Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts. ( Chandrasekhar, KB; Karthikeyan, K; Khan, FR; Kulkarni, NM; Narayanan, S; Nidhyanandan, S; Raghul, J; Reddy, ND; Thippeswamy, BS; Vijaykanth, G, 2017)
"Seven thyroid cancer cell lines (SNU-790, BCPAP, KTC1, TPC1, TPC1-M, KTC2, and FRO) and four HIF1α inhibitors (echinomycin, LAQ824, temsirolimus, and vorinostat) were used in the present study."1.42Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse model of thyroid cancer. ( Ahn, SH; Cha, W; Jeon, EH; Jeong, WJ; Kim, DW; Kim, SD, 2015)
"PaTu8988 pancreatic cancer cells were treated with different concentrations of suberoylanilide hydroxamic acid (SAHA), cell survival, proliferation, migration and vasculogenic mimicry (VM) were analyzed."1.40Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells. ( Cao, C; Cao, ZF; Pan, YY; Xu, XD; Yang, B; Yang, L; Zhang, ZQ; Zheng, LY; Zhou, QS, 2014)
"Current treatments for malignant gliomas produce only a modest increase in survival time."1.34Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. ( Bello, L; Black, PM; Carroll, RS; Kim, SK; Menon, LG; Ramakrishna, N; Ugur, HC, 2007)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (12.50)29.6817
2010's13 (81.25)24.3611
2020's1 (6.25)2.80

Authors

AuthorsStudies
Kang, DW1
Hwang, WC1
Noh, YN1
Kang, Y1
Jang, Y1
Kim, JA1
Min, DS1
Nidhyanandan, S1
Thippeswamy, BS1
Chandrasekhar, KB1
Reddy, ND1
Kulkarni, NM1
Karthikeyan, K1
Khan, FR1
Raghul, J1
Vijaykanth, G1
Narayanan, S1
Iizuka, N1
Morita, A1
Kawano, C1
Mori, A1
Sakamoto, K1
Kuroyama, M1
Ishii, K1
Nakahara, T1
Ghebremariam, YT1
Erlanson, DA1
Cooke, JP1
Xu, XD1
Yang, L1
Zheng, LY1
Pan, YY1
Cao, ZF1
Zhang, ZQ1
Zhou, QS1
Yang, B1
Cao, C1
Zhou, H1
Jiang, S1
Chen, J1
Su, SB1
Hiriyan, J1
Shivarudraiah, P1
Gavara, G1
Annamalai, P1
Natesan, S1
Sambasivam, G1
Sukumaran, SK1
Fu, S1
Hou, MM1
Naing, A1
Janku, F1
Hess, K1
Zinner, R1
Subbiah, V1
Hong, D1
Wheler, J1
Piha-Paul, S1
Tsimberidou, A1
Karp, D1
Araujo, D1
Kee, B1
Hwu, P1
Wolff, R1
Kurzrock, R2
Meric-Bernstam, F1
Cha, W1
Kim, DW1
Kim, SD1
Jeon, EH1
Jeong, WJ1
Ahn, SH1
Blattmann, C1
Oertel, S1
Thiemann, M1
Dittmar, A1
Roth, E1
Kulozik, AE1
Ehemann, V1
Weichert, W1
Huber, PE1
Stenzinger, A1
Debus, J1
Shankar, S1
Davis, R1
Singh, KP1
Ross, DD1
Srivastava, RK1
Jung, HJ1
Kim, JH1
Shim, JS1
Kwon, HJ1
Kim, JY1
Shim, G1
Choi, HW1
Park, J1
Chung, SW1
Kim, S1
Kim, K1
Kwon, IC1
Kim, CW1
Kim, SY1
Yang, VC1
Oh, YK1
Byun, Y1
Li, J1
Gong, C1
Feng, X1
Zhou, X1
Xu, X1
Xie, L1
Wang, R1
Zhang, D1
Wang, H1
Deng, P1
Zhou, M1
Ji, N1
Zhou, Y1
Wang, Y1
Wang, Z2
Liao, G1
Geng, N1
Chu, L1
Qian, Z1
Chen, Q1
Li, X1
Zhou, Q1
Hanus, J1
Anderson, C1
Zhang, H1
Dellinger, M1
Brekken, R1
Wang, S1
Ugur, HC1
Ramakrishna, N1
Bello, L1
Menon, LG1
Kim, SK1
Black, PM1
Carroll, RS1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies[NCT01339871]Phase 1152 participants (Actual)Interventional2011-04-20Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for vorinostat and Angiogenesis, Pathologic

ArticleYear
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chem

2015

Other Studies

15 other studies available for vorinostat and Angiogenesis, Pathologic

ArticleYear
Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma.
    Journal of cellular physiology, 2021, Volume: 236, Issue:1

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Chromatin; Drug Resistance, Neopl

2021
Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
    Anti-cancer drugs, 2017, Volume: 28, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Growth Processe

2017
Anti-angiogenic effects of valproic acid in a mouse model of oxygen-induced retinopathy.
    Journal of pharmacological sciences, 2018, Volume: 138, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Mice; Neovascularization, Pathologic; Oxyg

2018
A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide.
    The Journal of pharmacology and experimental therapeutics, 2014, Volume: 348, Issue:1

    Topics: Amidohydrolases; Cells, Cultured; Endothelium, Vascular; Female; Humans; Hydroxamic Acids; Imines; N

2014
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells.
    BMC cancer, 2014, May-27, Volume: 14

    Topics: Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Ne

2014
Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization.
    Canadian journal of physiology and pharmacology, 2014, Volume: 92, Issue:10

    Topics: ADAM Proteins; ADAMTS1 Protein; Administration, Ophthalmic; Animals; Apoptosis; Basic Helix-Loop-Hel

2014
Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Anticancer research, 2015, Volume: 35, Issue:1

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; HCT116 Cells; HeLa Cells; Histone D

2015
Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse model of thyroid cancer.
    Anticancer research, 2015, Volume: 35, Issue:4

    Topics: Animals; Apoptosis; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation, Neoplast

2015
Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.
    Radiation oncology (London, England), 2015, Jul-16, Volume: 10

    Topics: Animals; Apoptosis; Bone Neoplasms; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibit

2015
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:6

    Topics: Animals; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Ex

2009
A novel Ca2+/calmodulin antagonist HBC inhibits angiogenesis and down-regulates hypoxia-inducible factor.
    The Journal of biological chemistry, 2010, Aug-13, Volume: 285, Issue:33

    Topics: Animals; Benzoic Acid; Blotting, Western; Bridged Bicyclo Compounds; Calcium; Calmodulin; Cell Line;

2010
Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.
    Biomaterials, 2012, Volume: 33, Issue:17

    Topics: Animals; Antineoplastic Agents; Cations; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems

2012
Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell L

2012
Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model.
    Molecular pharmaceutics, 2013, Jan-07, Volume: 10, Issue:1

    Topics: Alkalies; Animals; Burns, Chemical; Cornea; Corneal Diseases; Corneal Injuries; Corneal Neovasculari

2013
Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model.
    Journal of neuro-oncology, 2007, Volume: 83, Issue:3

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Flow Cytometry; Gene Expression

2007